U.S. Intravenous Immunoglobulin Market Analysis & Forecast: 2026-2033

U.S. Intravenous Immunoglobulin Market Size and Share Analysis - 2026 To 2033

The U.S. Intravenous Immunoglobulin market is anticipated to grow at a CAGR of 8.2% with USD 8.79 Bn in 2026 and is expected to reach USD 10.03 Bn in 2033. The emerging prevalence of Kawasaki disease (more than 4,200 children are diagnosed with Kawasaki disease in the U.S. each year) is expected to bolster the growth of the U.S. intravenous immunoglobulin market. Kawasaki disease (KD), also known as Kawasaki syndrome, is an unknown etiology acute febrile illness that primarily affects children under the age of five.

Key Takeaways

• Liquid segment is expected to account the largest share of 60.0% in 2026. The segment dominates because it is operationally simpler, clinically faster, and better suited to modern hospital workflows than powder formulations. Median infusion time reduction by approximately 51% shorter with liquid IVIG.
• Primary Immunodeficiency Diseases will dominate with 40% in 2026. Even though PID is a “rare disease group”, it is still the largest immunoglobulin user group. Johns Hopkins Medicine notes that there are about 500,000 Americans with undiagnosed PIDDs.
• Hospital pharmacies will dominate with 65.0% in 2026. Hospital pharmacies as IVIG are a high-risk, hospital-administered biologic requiring clinical supervision, specialized storage, and integrated inpatient care systems. More than 2 Bn prescriptions were filled in 2025, with retail chains accounting for more than 40% and independent pharmacies just 17%.

Segmental Insights 

To learn more about this report, Request Free Sample

Why is Liquid Acquiring the Largest Market Share?

Liquid segment is projected to account for the largest share of formulation in 2026, representing approximately 60.0% of the total volume. The convenience as well as immediate usability of liquid IVIG products in clinical settings, particularly in hospitals and infusion centers is propelling the growth of the segment. These are key points of care for patients requiring immunoglobulin therapy. From Q1 2023 through Q4 2023, home IVIG visits gradually surged from 5,007 to 5,777, with an increase in every quarter.

Liquid IVIG is already ready to use, so doctors do not need to mix or prepare it before giving it to patients. This makes it faster as well as easier for healthcare staff to start treatment and saves time. This is especially important in hospitals as well as emergency situations, where patients need treatment in no time and doctors need to work efficiently with many patients at the same time.

Additionally, liquid IVIG products provide continuous dosing as well as reduced risk of contamination or administration errors, which significantly enhances patient safety as well as clinical results.

Primary Immunodeficiency Diseases holds the Largest Market Share

Based on application, Primary Immunodeficiency Diseases dominates the market, accounting for a significant 40% share in 2026. Primary Immunodeficiency Diseases contribute the highest share in the market owing to the critical role IVIG plays as a cornerstone therapy in managing these complex disorders. According to the Boston Children’s Hospital, around 1 in 2,000 (possibly more) people in America have a primary immunodeficiency disorder.

PIDs encompass a heterogeneous group of inherited disorders characterized by defects in the immune system, which leave affected individuals vulnerable to recurrent infections and immune dysregulation.

The Immune Deficiency Foundation (IDF), a leading non-profit organization in this field, has showed that IVIG administration remains a basic treatment for over 70 types of PIDs, making sure adequate antibody replacement for patients who cannot produce sufficient immunoglobulins on their own.

Hospital Pharmacies holds the Largest Market Share 

To learn more about this report, Request Free Sample

Based on distribution channel, hospital pharmacies dominant the market, accounting for a significant 65.0% share in 2026. Their critical role in the administration as well as management of intravenous immunoglobulin treatments, which are typically dispensed in controlled clinical environments is one of the factors propelling the market growth.

Hospital pharmacies are usually the preferred channel for IVIG distribution because of the complexity of the treatment along with the need for close medical supervision, given that IVIG is used to manage serious immune deficiencies, autoimmune diseases, and acute infections where precise dosage and monitoring are crucial.

For example, the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) show the importance of hospital-based administration of IVIG for conditions including primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), etc., where hospital pharmacies play a crucial role in handling the safety, efficacy, as well as proper handling of immunoglobulin products.

Advanced Healthcare Access and Rising Immunodeficiency Burden are Driving U.S. IVIG Industry Growth

The U.S. intravenous immunoglobulin industry is witnessing steady growth due to the country’s advanced healthcare infrastructure, extensive patient pool with immune deficiency disorders, as well as robust private and initiatives by government authorities supporting immunotherapy treatments. Common variable immunodeficiency (CVID) showed a prevalence of 15.4% in the US, 11.2% internationally, and 12.6% globally.

The sophisticated hospital network and comprehensive healthcare coverage, of the country facilitates widespread access to IVIG therapy for a variety of chronic and acute immunological conditions is fueling the market growth.

According to the U.S. National Institutes of Health (NIH), approximately 250,000 people are diagnosed with PIDD alone, demonstrating a major demand base for IVIG products. Furthermore, national organizations including the Immune Deficiency Foundation (IDF) contribute to awareness programs as well as patient support networks that advances diagnosis rates and treatment adherence, thereby sustaining demand growth.

Plasma Collection and Fractionation is transforming the U.S. Intravenous Immunoglobulin Industry

IVIG production begins with plasma collection from thousands of screened donors, where advanced automated plasmapheresis systems ensure safe, sterile, as well as efficient extraction of plasma. Since immunoglobulins represent only a small fraction of blood plasma, large-scale donor pooling is required to generate sufficient IgG for therapeutic use.

The collected plasma then goes through fractionation and purification, where the traditional Cohn cold ethanol method separates plasma proteins based on solubility differences, followed by modern chromatographic techniques including ion-exchange, affinity chromatography, etc. These enhanced purification steps make better IgG yield and purity while reducing unwanted proteins like IgA and IgM, thereby lowering the risk of adverse reactions and improving product safety and tolerability.

Viral Inactivation and Removal: A major breakthrough in U.S. Intravenous Immunoglobulin

Technologies including solvent/detergent (S/D) treatment, low pH incubation, nanofiltration, pasteurization, etc., are widely used to ensure strong viral safety in IVIG manufacturing. These methods work together as multiple “barrier steps” that inactivate or remove both enveloped as well as non-enveloped viruses, significantly reducing the risk of blood-borne pathogen transmission during production.

Companies such as Baxalta (now part of Takeda) and Octapharma have implemented multi-layer viral reduction strategies in their manufacturing processes, combining chemical inactivation and physical filtration techniques. This has greatly improved the overall safety profile of IVIG products and has been a key factor supporting broader regulatory approvals and clinical acceptance worldwide.

Current Events and Their Impact on the U.S. Intravenous Immunoglobulin Market (regulatory shifts, government policies)

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

U.S. Intravenous Immunoglobulin Market Trends

• Rising incidence of chronic inflammatory and autoimmune diseases such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), and primary immunodeficiencies are driving IVIG consumption. Each year in the United States, an estimated 3,000 to 6,000 people develop Guillain-Barré syndrome, thereby creating sustained demand for IVIG therapy as a key treatment option for immune-mediated neurological disorders.
• Expanding application spectrum beyond traditional indications, including neurological, hematological, infectious diseases, etc. The U.S. reported over 2,000 measles cases in 2025, the highest annual total in decades and by far the most since the disease was declared eliminated in the country.
• High adoption of subcutaneous immunoglobulin (SCIG) therapies, complementing IVIG, to improve patient convenience as well as reduce adverse effects.
• Technological innovations are advancing IVIG purification processes as well as formulation stability.
• Building collaborations among biopharmaceutical companies to develop next-generation immunoglobulin products.

Who are the Major Companies in U.S. Intravenous Immunoglobulin Industry

Some of the major key players in U.S. Intravenous Immunoglobulin market include, Biotest AG, Octapharma AG, Grifols S.A., Kedrion Biopharma, Inc., CSL Behring, McKesson Corporation, Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Pfizer, Inc., and ADMA Biologics, Inc.

Key News

• In January 2026, Takeda announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, approved as replacement therapy for people two years of age and older with primary immunodeficiency (PI). GAMMAGARD LIQUID ERC is a liquid immunoglobulin therapy that does not require reconstitution and has a low immunoglobulin A (IgA) content less than or equal to 2 µg/mL in a 10% solution to be administered intravenously or subcutaneously.
• In September 2025, Kedrion Biopharma announced that the U.S. Food and Drug Administration (FDA) has approved Qivigy™ (10% intravenous immunoglobulin) for the treatment of adults with primary humoral immunodeficiency (PI) a group of serious and often underdiagnosed disorders that compromise immune function.

Market Report Scope 

Analyst Opinion

• The U.S. intravenous immunoglobulin (IVIG) market is witnessing significant momentum driven by increasing prevalence of autoimmune and chronic inflammatory diseases, such as primary immunodeficiency disorders, chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barré syndrome. In 2023, the adjusted incidence rate for CIDP in the US was 2.8 per 100,000 persons, corresponding to approximately 9238 new cases.
• High awareness among healthcare providers as well as improved diagnostic rates are further augmenting demand for IVIG therapies. Additionally, advancements in plasma collection with purification technologies have enhanced the safety as well as efficacy of IVIG products, showing greater physician as well as patient confidence.
• However, the market faces challenges with the high cost associated with IVIG treatments as well as limited plasma supply, which could limit accessibility and pricing stability.
• Moreover, some patients may have serious side effects, which can make it harder for more people to use these treatments, especially people who are more sensitive or at higher risk. Also, strict government rules for plasma-based medicines make the market more complex. Because of this, companies must keep improving their products and also follow all safety rules carefully.
• Opportunities abound in expanding therapeutic indications, with ongoing research into novel applications including neurodegenerative diseases as well as advancing infectious conditions. An estimated 7.4 million Americans age 65 and older live with clinical Alzheimer's dementia today.
• The development of next-generation immunoglobulin products with improved administration protocols, including subcutaneous formulations, offers enhanced convenience with patient adherence, augmenting market growth prospects.

Market Segmentation

• By Formulation
  • Liquid
  • Powder
• By Application
  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Primary Immunodeficiency Diseases
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Kawasaki Disease
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Sources

Primary Research Interviews

• Biopharmaceutical Company Executives
• Hospital Pharmacy Directors
• Healthcare Payers and Insurance Representatives
• Clinicians/Immunologists
• Others

Databases

• IQVIA
• ClinicalTrials.gov
• EvaluatePharma
• Others

Magazines

• Pharmaceutical Technology
• Drug Development & Delivery
• BioPharma Dive
• Others

Journals

• Journal of Clinical Immunology
• Journal of Immunotherapy
• Immunology Letters
• Others

Newspapers

• The Wall Street Journal - Health Section
• The New York Times - Health Section